Innovative spiral electrode configuration for enhancement of electrocoagulation-flotation.

The performance of electrocoagulation-flotation (ECF) process can profoundly be affected by the reactor design and electrode configuration. These may, in turn, influence the removal efficiency, flow hydrodynamic, floc formation, and flotation/settling characteristics. The present work aimed at developing a new spiral electrode configuration to enhance the ECF process.

Flax Fibre Yarn Coated with Lignin from Renewable Sources for Composites.

The present experimental work analyses the potential of lignin as a matrix for materials made from renewable resources for composite components and the production of hybrid semi-finished products by coating a flax fibre yarn. Natural fibres, due to their low density, in combination with lignin can be a new renewable source for lightweight products. For this purpose, the extrusion process was adapted to lignin as a matrix material for bio-based composites and coating of natural fibre yarns.

Development of Natural Fibre-Reinforced Semi-Finished Products with Bio-Based Matrix for Eco-Friendly Composites.

Increasing resource consumption and a growing amount of textile waste increase the importance of a circular economy and recycling in the fashion and apparel industry. Environmentally friendly bio-based composites made from cellulosic fibres obtained from textile waste, and polymers based on renewable raw materials present a possible solution. In this study, the development of textile semi-finished products based on medium-to-long cotton and flax fibres obtained from textile waste in combination with a bio-based thermoplastic matrix for lightweight applications is investigated.

Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.

Background: We have recently reported on a recombinant von Willebrand factor (VWF) D'D3 albumin fusion protein (rD'D3-FP) developed to extend the half-life of coagulation factor VIII (FVIII) for the treatment of hemophilia A. Based on predictive modelling presented in this study, we hypothesized that modifying rD'D3-FP to improve FVIII interaction would reduce exchange with endogenous VWF and provide additional FVIII half-life benefit.

Objectives: The aim of this study was to identify novel rD'D3-FP variants with enhanced therapeutic efficacy in extending FVIII half-life.

Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.

Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing antibodies against these factors represents serious complications underlining the need for alternative treatment approaches. Human coagulation factor X has a central role within the blood coagulation system making it an attractive target for the development of alternative treatment strategies for patients with hemophilia.

FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

A novel mechanism for extending the circulatory half-life of coagulation factor VIII (FVIII) has been established and evaluated preclinically. The FVIII binding domain of von Willebrand factor (D'D3) fused to human albumin (rD'D3-FP) dose dependently improved pharmacokinetics parameters of coadministered FVIII in all animal species tested, from mouse to cynomolgus monkey, after IV injection. At higher doses, the half-life of recombinant FVIII (rVIII-SingleChain) was calculated to be increased 2.

FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.

Haemostasis including blood coagulation is initiated upon vessel wall injury and indispensable to limit excessive blood loss. However, unregulated pathological coagulation may lead to vessel occlusion, causing thrombotic disorders, most notably myocardial infarction and stroke. Furthermore, blood exposure to foreign surfaces activates the intrinsic pathway of coagulation.

The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats.

Background And Purpose: Ischemic stroke provokes severe brain damage and remains a predominant disease in industrialized countries. The coagulation factor XII (FXII)-driven contact activation system plays a central, but not yet fully defined pathogenic role in stroke development. Here, we investigated the efficacy of the FXIIa inhibitor rHA-Infestin-4 in a rat model of ischemic stroke using both a prophylactic and a therapeutic approach.

Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Introduction: rVIII-SingleChain (CSL627), a novel recombinant coagulation factor VIII (FVIII), is under investigation in a phase I/III clinical programme (AFFINITY) for the treatment of haemophilia A. Non-clinical studies were conducted to investigate the pharmacokinetic/pharmacodynamic profile of rVIII-SingleChain in comparison with full-length recombinant FVIII.

Materials And Methods: Binding affinity of rVIII-SingleChain for von Willebrand factor was investigated by surface plasmon resonance analysis.

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

Background: Recombinant factor VIIa (rFVIIa) is approved for use in controlling bleeding episodes in people with hemophilia who have developed inhibitors to replacement therapy. Due to its short half-life (t½), frequent injections are required, limiting its use as a prophylactic treatment. A novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) has been developed to extend the t(½) of rFVIIa.

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.

The prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due to the suboptimal half-lives of the products commercially available and currently in use, e.g. recombinant factor IX (rFIX) and recombinant factor VIIa (rFVIIa), respectively.

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Introduction: The preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII, was assessed in a series of animal studies.

Materials And Methods: In the tail-clip bleeding model, hemophilia A mice were injected with escalating doses (1-150 IU/kg) of rVIII-SingleChain, B-domain deleted (BDD) rFVIII (ReFacto AF(®)), or full-length rFVIII products (Advate(®), Helixate(®)). Total blood loss and the percentage of animals in which hemostasis occurred were assessed in this observer-blinded, randomized study.

Neuropathy following laparoscopic adjustable gastric banding: treatment with plasmapheresis.

Laparoscopic adjustable gastric banding is being increasingly utilized for therapy of obesity in the United States. It is a relatively newer technique and little is known about neurologic complications resulting from this procedure. We present a case of disabling peripheral neuropathy occurring after gastric banding.

Neurosurgical therapy for central area status epilepticus.

The authors report a case of status epilepticus localized to sensorimotor cortex that was successfully treated with surgical resection and multiple subpial transections (MST). A 43 year old woman presented in status epilepticus emanating from a right central area focus as verified by subdural grid and strip electrodes. The seizures were medically intractable but were successfully aborted after surgical intervention.

Identification of the e allele at the Extension locus (MC1R) in Brazilian Creole sheep and its role in wool color variation.

The melanocortin 1 receptor (MC1R) gene has been described as responsible for the black color in some breeds of sheep, but little is known about its function in many colored breeds, particularly those with a wide range of pigmentation phenotypes. The Brazilian Creole is a local breed of sheep from southern Brazil that has a wide variety of wool colors. We examined the MC1R gene (Extension locus) to search for the e allele and determine its role in controlling wool color variation in this breed.

Mitochondrial and nuclear DNA analyses reveal population differentiation in Brazilian Creole sheep.

Using ND5 sequences from mtDNA and 10 nuclear markers, we investigated the genetic differentiation of two South American Creole sheep phenotypes that historically have been bred in different biomes in southern Brazil. In total, 18 unique mtDNA haplotypes were detected, none of which was shared between the two phenotypes. Bayesian analysis also indicated two different groups (k = 2).

Clinical pathology and parasitologic evaluation of free-living nestlings of the Hyacinth Macaw (Anodorhynchus hyacinthinus).

This study evaluated the health status and established hematologic and serum biochemistry parameters for free-living nestlings of the Hyacinth Macaw (Anodorhynchus hyacinthinus) from the Brazilian Pantanal (19 degrees 51'-19 degrees 58'S; 56 degrees 17'-56 degrees 24'W), for four consecutive years (from December 2003 through December 2006). Physical examinations indicated that all the birds were in good health. Endoparasites and blood parasites were not detected in any of the nestlings, and ectoparasites seemed to be limited to Philornis sp.

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

Haemophilia B is a X-chromosome linked disease characterised by a deficiency of functionally active coagulation Factor IX (FIX). Patients with severe haemophilia B at risk of recurrent bleeding are treated approximately twice a week in a prophylactic setting by application of FIX concentrates. To increase convenience and compliance of the therapy it is desirable to reduce the dosing frequency by improving the pharmacokinetic properties of FIX.

Structure-function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions.

Factor VII activating protease (FSAP) is associated with cardiovascular diseases and liver fibrosis. To understand the regulation of its proteolytic activity we have characterized recombinant FSAP-mutants over-expressed in HEK-293 cells. The secreted FSAP-protein concentration correlated inversely with the enzymatic activity of the FSAP-mutants.

Temporal lobectomy for refractory status epilepticus in a case of limbic encephalitis.

The authors report a case of status epilepticus secondary to limbic encephalitis that was successfully treated with temporal lobectomy. A 45-year-old woman presented in status epilepticus refractory to high-dose suppressive medical therapy. Magnetic resonance imaging of the brain showed T2- and FLAIR-weighted hyperintensities in the right temporal lobe, left and right frontal lobes, and pons.

Molecular diagnosis of Salmonella species in captive psittacine birds.

Cloacal swabs were collected from 280 captive psittacine birds belonging to 13 species. Samples of dna were tested by PCR using a pair of primers that amplify a 284 base pair fragment of the Salmonella genus invA gene, and the PCR-positive samples were tested by standard microbiological techniques. Thirteen per cent of the samples were positive by PCR, but negative by microbiological techniques.

Prolonged in-vivo half-life of factor VIIa by fusion to albumin.

For the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy. However, the short in-vivo half-life of approximately 2.5 hours makes multiple injections necessary, which is inconvenient for both physicians and patients.

Effect of polymorphisms linked to LEP gene on its expression on adipose tissues in beef cattle.

In cattle, genetic markers at the leptin (LEP) gene and at those linked to the gene have been described as affecting calving interval (markers LEPSau3AI and IDVGA51), or daily weight gain (BMS1074 and BM1500). This work investigated the effect of these alleles on LEP mRNA levels in cattle subcutaneous and omental adipose tissues. A sample of 137 females of a Brangus-Ibage beef cattle herd was analysed to evaluate the distribution of the polymorphisms; then, animals having at least one of the IDVGA51*181 (allele 181 at marker IDVGA51; six animals), LEPSau3AI*2 (four), BMS1074*151 (13), BM1500*135 (six) alleles and a control group composed of animals without any of these alleles (four animals) were submitted to surgery to obtain omental and subcutaneous adipose tissues.

The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.

The G534E polymorphism (Marburg I [MI]) of factor VII-activating protease (FSAP) is associated with carotid stenosis and cardiovascular disease. We have previously demonstrated that FSAP is present in atherosclerotic plaques and it is a potent inhibitor of vascular smooth muscle proliferation and migration in vitro. The effect of wild-type (WT)- and MI-FSAP on neointima formation in the mouse femoral artery after wire-induced injury was investigated.